Patents by Inventor Se-In Chang
Se-In Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11254724Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.Type: GrantFiled: November 14, 2019Date of Patent: February 22, 2022Assignee: Hanmi Pharm. Co., Ltd.Inventors: Sung Youb Jung, Young Jin Park, Jong Suk Lee, Jae Hyuk Choi, Chang Ki Lim, Se Chang Kwon
-
Publication number: 20220025012Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.Type: ApplicationFiled: October 12, 2021Publication date: January 27, 2022Inventors: Sung Youb JUNG, Young Jin PARK, Jong Suk LEE, Jae Hyuk CHOI, Chang Ki LIM, Se Chang KWON
-
Publication number: 20210404082Abstract: A process for the large scale manufacturing of vertically standing hybrid nanometer-scale structures of different geometries, including fractal architecture made of flexible materials, on a flexible substrate including textiles is disclosed. The nanometer-scale structures increase the surface area of the substrate. The nanometer-scale structures may be coated with materials that are sensitive to various physical parameters or chemicals such as but not limited to temperature, humidity, pressure, atmospheric pressure, electromagnetic signals originating from biological or non-biological sources, volatile gases, and pH. The increased surface area achieved through the disclosed process is intended to improve the sensitivity of the sensors formed by coating of the nanometer-scale structure and substrate with a material which can be used to sense physical parameters and chemicals as listed previously.Type: ApplicationFiled: August 5, 2021Publication date: December 30, 2021Applicant: NANOWEAR INC.Inventors: Vijay K. Varadan, Pratyush Rai, Se Chang Oh
-
Patent number: 11207383Abstract: Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.Type: GrantFiled: October 28, 2019Date of Patent: December 28, 2021Assignee: HANMI PHARM. CO., LTDInventors: Dae Jin Kim, Jong Soo Lee, Young Jin Park, Sung Hee Hong, Sung Min Bae, Se Chang Kwon
-
Patent number: 11189349Abstract: A memory device includes an erase operation controller for performing an erase operation on a memory block; an erase suspend count manager for managing an erase suspend count representing a number of times the erase operation is suspended until the erase operation on the memory block is completed; and a program parameter value determiner for determining a parameter value to be used for a program operation on the memory block, based on the erase suspend count.Type: GrantFiled: November 4, 2020Date of Patent: November 30, 2021Assignee: SK hynix Inc.Inventor: Se Chang Park
-
Patent number: 11168109Abstract: Disclosed is a method for the preparation of a complex in which a physiologically active polypeptide is covalently bonded to an immunoglobulin constant region via a non-peptidyl linker. The method is characterized by the employment of a reducing agent, by which conventional problems of low production yield and modification of the polypeptide can be overcome. The physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be produced with high purity and yield as well as at low cost. Thus, the method is industrially useful. Moreover, by exhibiting a prolonged action profile, the physiologically active polypeptide-non-peptidyl polymer-immunoglobulin constant region complex can be effectively used for developing long-acting formulations of physiologically active polypeptides which have improved drug compliance.Type: GrantFiled: March 8, 2013Date of Patent: November 9, 2021Assignee: HANMI SCIENCE CO., LTD.Inventors: Myung Hyun Jang, Min Young Kim, Jong-soo Lee, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 11135271Abstract: The present invention relates to a novel glucagon derivative peptide, and a composition for preventing or treating hypoglycemia containing the novel glucagon derivative peptide as an active ingredient. The glucagon derivative according to the present invention has improved physical properties due to the change in isoelectric point (pI) while being capable of maintaining an activity on glucagon receptors, and thus can improve patient compliance when used as a hypoglycemic agent, and is also suitable for administration in combination with other anti-obesity agents. Accordingly, the glucagon derivative according to the present invention can be effectively used for the prevention and treatment of hypoglycemia and obesity.Type: GrantFiled: December 30, 2015Date of Patent: October 5, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Jung Kuk Kim, Jong Min Lee, Sang Yun Kim, Sung Min Bae, Sung Youb Jung, Se Chang Kwon
-
Patent number: 11123436Abstract: Provided is a method of preparing a physiologically active polypeptide conjugate, in which a physiologically active polypeptide and a non-peptidyl polymer are linked to each other via a covalent bond. The method is to improve an overall yield of the physiologically active polypeptide conjugate by improving a reaction of the non-peptidyl polymer and the physiologically active polypeptide, and particularly, the method is to prepare a physiologically active polypeptide conjugate in a high yield by performing a two-step reaction through selective precipitation. The preparation method of the present invention is used to produce a non-peptidyl polymer-physiologically active polypeptide conjugate and a physiologically active polypeptide-physiologically active carrier conjugate in a high yield, and therefore, the method may be used in the development of long-acting formulations of various peptide drugs which maintain in vivo activity at a relatively high level and have remarkably increased blood half-life.Type: GrantFiled: July 22, 2016Date of Patent: September 21, 2021Inventors: Sun Jin Moon, Cheong Byeol Shin, Sung Hee Hong, Dae Jin Kim, Se Chang Kwon
-
Patent number: 11111593Abstract: A process for the large scale manufacturing of vertically standing hybrid nanometer-scale structures of different geometries, including fractal architecture made of flexible materials, on a flexible substrate including textiles is disclosed. The nanometer-scale structures increase the surface area of the substrate. The nanometer-scale structures may be coated with materials that are sensitive to various physical parameters or chemicals such as but not limited to temperature, humidity, pressure, atmospheric pressure, electromagnetic signals originating from biological or non-biological sources, volatile gases, and pH. The increased surface area achieved through the disclosed process is intended to improve the sensitivity of the sensors formed by coating of the nanometer-scale structure and substrate with a material which can be used to sense physical parameters and chemicals as listed previously.Type: GrantFiled: January 14, 2016Date of Patent: September 7, 2021Assignee: Nanowear Inc.Inventors: Vijay K. Varadan, Pratyush Rai, Se Chang Oh
-
Patent number: 11071785Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.Type: GrantFiled: March 18, 2019Date of Patent: July 27, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 11058776Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.Type: GrantFiled: March 12, 2019Date of Patent: July 13, 2021Assignee: HANMI SCIENCE CO., LTD.Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
-
Patent number: 11047051Abstract: A process for the large-scale manufacturing vertically standing hybrid nanometer scale structures of different geometries including fractal architecture of nanostructure within a nano/micro structures made of flexible materials, on a flexible substrate including textiles is disclosed. The structures increase the surface area of the substrate. The structures maybe coated with materials that are sensitive to various physical parameters or chemicals such as but not limited to humidity, pressure, atmospheric pressure, and electromagnetic signals originating from biological or non-biological sources, volatile gases and pH. The increased surface area achieved through the disclosed process is intended to improve the sensitivity of the sensors formed by coating of the structure and substrate with a material which can be used to sense physical parameters and chemicals as listed previously.Type: GrantFiled: October 18, 2018Date of Patent: June 29, 2021Assignee: NANOWEAR INC.Inventors: Vijay K. Varadan, Pratyush Rai, Se Chang Oh
-
Publication number: 20210188937Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.Type: ApplicationFiled: February 26, 2021Publication date: June 24, 2021Applicant: HANMI PHARM. CO., LTD.Inventors: Euh Lim OH, Jong Suk LEE, Young Jin PARK, Chang Ki LIM, Sung Youb JUNG, Se Chang KWON
-
Patent number: 11040110Abstract: Disclosed is a protein complex, comprising a physiologically active polypeptide, a dimeric protein and a non-peptidyl polymer having three functional ends (3-arm), with the linkage of both the physiologically active polypeptide and the dimeric protein to the 3-arm non-peptidyl polymer via respective covalent bonds. The protein complex guarantees the long acting activity and biostability of a physiologically active polypeptide. Having the ability to maintain the bioactivity of physiologically active polypeptides or peptides highly and to significantly improve the serum half life of the polypeptides or peptides, the protein complex can be applied to the development of sustained release formulations of various physiologically active polypeptide drugs. Also, it utilizes raw materials including the physiologically active polypeptides without significant loss, thereby increasing the production yield. Further, it can be easily purified.Type: GrantFiled: August 7, 2018Date of Patent: June 22, 2021Assignee: HANMI SCIENCE CO., LTD.Inventors: Dae Hae Song, Jae Hee Shin, Mi Ji Lee, Sung Hee Hong, Se Chang Kwon, Gwan Sun Lee
-
Publication number: 20210177335Abstract: A non-invasive, wearable and portable medical device for evaluation and monitoring the heart condition for patients with congestive heart failure and a CHF management system is provided comprising a wearable textile-based device utilizing physiologic and biometric sensors, a Signal Acquisition Unit, and a monitoring system executing a suite of software algorithms to monitor and evaluate patients with CHF.Type: ApplicationFiled: February 11, 2021Publication date: June 17, 2021Applicant: NANOWEAR INC.Inventors: Vijay Varadan, Pratyush Rai, Se Chang Oh, Prashanth Shyam Kumar, Mouli Ramasamy
-
Publication number: 20210138070Abstract: A sustained release preparation of a human growth hormone conjugate is disclosed. The sustained release preparation contains a sustained release human growth hormone (hGH) conjugate resulting from conjugation between an immunoglobulin Fc region and a human growth hormone (hGH) as an active peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. A freeze dried preparation and a liquid preparation including the sustained release human growth hormone conjugate, a production method for the freeze dried preparation, a method of reconstituting the freeze dried preparation, and a kit containing the freeze dried preparation and a reconstituting solution are also disclosed.Type: ApplicationFiled: December 28, 2020Publication date: May 13, 2021Applicant: HANMI PHARM. CO., LTD.Inventors: Hwa Peoung RIM, Hyun Uk KIM, Ho Taek IM, Sang Yun KIM, Hyung Kyu LIM, Sung Min BAE, Se Chang KWON
-
Patent number: 10987425Abstract: The present invention relates to a sustained type human growth hormone conjugate preparation comprising: a sustained type human growth hormone (hGH) conjugate resulting from conjugation between the immunoglobulin Fc region and a human growth hormone (hGH) constituting a bioactive peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. More specifically, the present invention relates to a sustained type human growth hormone conjugate freeze dried preparation and liquid preparation, to a production method for the freeze dried preparation, to a method of reconstituting the freeze dried preparation, and to a kit comprising the freeze dried preparation and a reconstituting solution.Type: GrantFiled: September 26, 2014Date of Patent: April 27, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Hwa Peoung Rim, Hyun Uk Kim, Ho Taek Im, Sang Yun Kim, Hyung Kyu Lim, Sung Min Bae, Se Chang Kwon
-
Patent number: 10987424Abstract: The present invention relates to a liquid formulation of long-acting insulin conjugate, comprising a pharmaceutically effective amount of a long-acting insulin conjugate, wherein a physiologically active peptide, which is an insulin, is linked to an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, a non-ionic surfactant, and an isotonic agent, and a method for preparing the formulation. For preventing microbial contamination in multiple uses, a preservative can be added to the formulation. The liquid formulation of the present invention does not comprise a human serum albumin and potentially hazardous factors to body, and thus it has excellent storage stability for insulin conjugate without a risk of viral infection.Type: GrantFiled: July 25, 2013Date of Patent: April 27, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Hyung Kyu Lim, Hyun Uk Kim, Sung Hee Hong, Min Young Kim, Sung Min Bae, Se Chang Kwon
-
Patent number: 10981967Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.Type: GrantFiled: January 31, 2019Date of Patent: April 20, 2021Assignee: HANMI PHARM. CO., LTD.Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
-
Patent number: 10959634Abstract: A non-invasive, wearable and portable medical device for evaluation and monitoring the heart condition for patients with congestive heart failure and a CHF management system is provided comprising a wearable textile-based device utilizing physiologic and biometric sensors, a Signal Acquisition Unit, and a monitoring system executing a suite of software algorithms to monitor and evaluate patients with CHF.Type: GrantFiled: May 1, 2018Date of Patent: March 30, 2021Assignee: NANOWEAR INC.Inventors: Vijay Varadan, Pratyush Rai, Se Chang Oh, Prashanth Shyam Kumar, Mouli Ramasamy